A Large Cluster of New Onset Autoimmune Myositis in the Yorkshire Region Following SARS-CoV-2 Vaccination

Autor: Gabriele De Marco, Sami Giryes, Katie Williams, Nicola Alcorn, Maria Slade, John Fitton, Sharmin Nizam, Gayle Smithson, Khizer Iqbal, Gui Tran, Katrina Pekarska, Mansoor Ul Haq Keen, Mohammad Solaiman, Edward Middleton, Samuel Wood, Rihards Buss, Kirsty Devine, Helena Marzo-Ortega, Mike Green, Dennis McGonagle

Publikováno v: Vaccines, Vol 10, Iss 8, p 1184 (2022)

Background: The novel SARS-CoV-2 vaccines partially exploit intrinsic DNA or RNA adjuvanticity, with dysregulation in the metabolism of both these nucleic acids independently linked to triggering experimental autoimmune diseases, including lupus and

Externí odkaz: https://doaj.org/article/b024fff9284d4932bfedc5ad788f00e3

Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway

Autor: Maya H Buch, Jacqueline L Nam, John Fitton, Andrew Melville, Paul Emery

Publikováno v: Fitton, J, Melville, A R, Emery, P, Nam, J L & Buch, M H 2020, ' Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway ', Rheumatology . https://doi.org/10.1093/rheumatology/keaa858

Objectives To evaluate real-world efficacy of approved JAK inhibitors (JAKi) tofacitinib and baricitinib in a large, single-centre cohort of RA patients across the treatment pathway, including those refractory to multiple biologic drugs. Methods All

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d59f5f5385ae8694d9b5af2bd4b64999
https://doi.org/10.1093/rheumatology/keaa858

OUP accepted manuscript

Autor: Benazir Saleem, Lynda Bailey, Shouvik Dass, Paul Emery, Andrew Melville, L. Garcia-Montoya, Maya H Buch, Yuzaiful Md Yusof, John Fitton

Publikováno v: Rheumatology.

Objective To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with RA. Methods Between October 2017 and October 2019, all patients on RTX-O in our centre requiring re-treatment were switche

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e750a1d3bf5db071a3d406e66c98c1fd
https://doi.org/10.1093/rheumatology/keaa834

THU0175 REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS

Autor: Benazir Saleem, Yuzaiful Md Yusof, John Fitton, Andrew Melville, Lynda Bailey, Maya H Buch, Paul Emery, Shouvik Dass

Publikováno v: Annals of the Rheumatic Diseases. 79:303-304

Background:Pre-clinical and trial data confirm biosimilar rituximab (RTX-B) has equivalent physicochemical properties, function, efficacy and safety as originator (RTX-O)1,2. However, real-world data are lacking, including non-medical switch to RTX-B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc420d05999e5b0abe6c5206676f0f1c
https://doi.org/10.1136/annrheumdis-2020-eular.4534

FRI0090 SINGLE CENTRE COHORT OF REFRACTORY RHEUMATOID ARTHRITIS ALSO IDENTIFIES A RARE SUBGROUP OF MULTIPLE TARGETED THERAPY CLASS NON-RESPONSE

Autor: Jacqueline L Nam, Kamran Naraghi, John Fitton, Shouvik Dass, Andrew Melville, Maya H Buch, Paul Emery

Publikováno v: Poster Presentations.

Background: Refractory Rheumatoid Arthritis (RefRA) has emerged as an area of unmet need in the biologic era (1). Failure of 3 or more classes of targeted therapy or failure of both an anti-cytokine and a cell-targeted treatment have been proposed as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::10963d2f9b1c5b70114d30b1844ffa2e
https://doi.org/10.1136/annrheumdis-2019-eular.7444